Nurix Therapeutics, Inc. (NRIX)
22.14
-0.21
(-0.94%)
USD |
NASDAQ |
Oct 12, 16:00
22.52
+0.38
(+1.72%)
After-Hours: 20:00
Nurix Therapeutics Max Drawdown (5Y) : 91.53% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 91.53% |
| August 31, 2026 | 91.53% |
| July 31, 2026 | 91.53% |
| June 30, 2026 | 91.53% |
| May 31, 2026 | 91.53% |
| April 30, 2026 | 91.53% |
| March 31, 2026 | 91.53% |
| February 28, 2026 | 91.53% |
| January 31, 2026 | 91.53% |
| December 31, 2025 | 91.53% |
| November 30, 2025 | 91.53% |
| October 31, 2025 | 91.53% |
| September 30, 2025 | 91.53% |
| August 31, 2025 | 91.53% |
| July 31, 2025 | 91.53% |
| June 30, 2025 | 91.53% |
| May 31, 2025 | 91.53% |
| April 30, 2025 | 91.53% |
| March 31, 2025 | 91.53% |
| February 28, 2025 | 91.53% |
| January 31, 2025 | 91.53% |
| December 31, 2024 | 91.53% |
| November 30, 2024 | 91.53% |
| October 31, 2024 | 91.53% |
| September 30, 2024 | 91.53% |
| Date | Value |
|---|---|
| August 31, 2024 | 91.53% |
| July 31, 2024 | 91.53% |
| June 30, 2024 | 91.53% |
| May 31, 2024 | 91.53% |
| April 30, 2024 | 91.53% |
| March 31, 2024 | 91.53% |
| February 29, 2024 | 91.53% |
| January 31, 2024 | 91.53% |
| December 31, 2023 | 91.53% |
| November 30, 2023 | 91.53% |
| October 31, 2023 | 91.53% |
| September 30, 2023 | 84.33% |
| August 31, 2023 | 84.29% |
| July 31, 2023 | 84.29% |
| June 30, 2023 | 84.29% |
| May 31, 2023 | 84.29% |
| April 30, 2023 | 84.29% |
| March 31, 2023 | 84.29% |
| February 28, 2023 | 84.29% |
| January 31, 2023 | 84.29% |
| December 31, 2022 | 84.29% |
| November 30, 2022 | 84.29% |
| October 31, 2022 | 84.29% |
| September 30, 2022 | 84.29% |
| August 31, 2022 | 84.29% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Gilead Sciences, Inc. | 26.58% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Anika Therapeutics, Inc. | 83.15% |
| Savara, Inc. | 93.79% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -26.56 |
| Beta (5Y) | 1.819 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 74.43% |
| Historical Sharpe Ratio (5Y) | -0.1123 |
| Historical Sortino (5Y) | -0.2442 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 28.11% |